Abstract：
PET imaging, particularly using amino acid tracers, has become a valuable adjunct to anatomical MRI in the clinical management of patients with glioma. Collaborative international efforts have led to the development of clinical and technical guidelines for PET imaging in gliomas. The increasing readiness of statutory health insurance agencies, especially in European countries, to reimburse amino acid PET underscores its growing importance in clinical practice. Integrating artificial intelligence and radiomics in PET imaging of patients with glioma may significantly improve tumor detection, segmentation, and response assessment. Efforts are ongoing to facilitate the clinical translation of these techniques. Considerable progress in computer technology developments (eg quantum computers) may be helpful to accelerate these efforts. Next-generation PET scanners, such as long-axial field-of-view PET/CT scanners, have improved image quality and body coverage and therefore expanded the spectrum of indications for PET imaging in Neuro-Oncology (eg PET imaging of the whole spine). Encouraging results of clinical trials in patients with glioma have prompted the development of PET tracers directing therapeutically relevant targets (eg the mutant isocitrate dehydrogenase) for novel anticancer agents in gliomas to improve response assessment. In addition, the success of theranostics for the treatment of extracranial neoplasms such as neuroendocrine tumors and prostate cancer has currently prompted efforts to translate this approach to patients with glioma. These advancements highlight the evolving role of PET imaging in Neuro-Oncology, offering insights into tumor biology and treatment response, thereby informing personalized patient care. Nevertheless, these innovations warrant further validation in the near future.
摘要：
PET成像,特别是使用氨基酸示踪剂，在胶质瘤患者的临床治疗中，已成为解剖MRI的有价值的辅助手段。国际合作的努力导致了神经胶质瘤PET成像的临床和技术指南的开发。法定健康保险机构的日益准备，尤其是在欧洲国家,偿还氨基酸PET强调了其在临床实践中的重要性。在胶质瘤患者的PET成像中整合人工智能和影像组学可以显着提高肿瘤的检测，分割，和反应评估。正在努力促进这些技术的临床翻译。计算机技术发展的相当大的进步（例如量子计算机）可能有助于加速这些努力。下一代PET扫描仪,如长轴视场PET/CT扫描仪，改善了图像质量和身体覆盖率，因此扩大了神经肿瘤学PET成像的适应症范围（例如整个脊柱的PET成像）。神经胶质瘤患者临床试验的令人鼓舞的结果促使PET示踪剂的开发，这些示踪剂指导神经胶质瘤中新型抗癌剂的治疗相关靶标（例如突变的异柠檬酸脱氢酶），以改善反应评估。此外,治疗颅外肿瘤如神经内分泌肿瘤和前列腺癌的成功目前促使人们努力将这种方法应用于神经胶质瘤患者.这些进步突出了PET成像在神经肿瘤学中不断发展的作用，提供对肿瘤生物学和治疗反应的见解，从而通知个性化的病人护理。然而，这些创新在不久的将来值得进一步验证。
